Tegafur (CAS: 17902-23-7)

Appearance: this product is a white crystalline powder; Odourless. This product in methanol, propanol, or dissolved in chloroform, slightly soluble in water or ethanol, almost insoluble in benzene or ethyl ether.

Dynamics

Good oral absorption, 2 hours peak effect after the treatment, plasma T1/2 to 5 hours, uniform distribution at high concentration in liver, kidney, intestine, spleen and brain, concentration in the liver and kidney as the highest. Because this product has the high lipid solubility, can through the blood brain barrier, concentration in the cerebrospinal fluid is higher than fluorouracil. This product by the liver metabolism, mainly through the urinary, and respiratory, medication within 24 hours after the urine to the prototype from 23%, 55% through the respiratory tract in the form of carbon dioxide.

Adaptation disease

Main treatment of digestive tract cancer, stomach cancer, colon cancer, rectal cancer, and pancreatic cancer, for instance, can also be used to treat breast, bronchial lung cancer and liver cancer, etc.

Adverse reactions

Mild bone marrow suppression of white blood cells and thrombocytopenia. Mild gastrointestinal reaction is given priority to with loss of appetite and nausea, individual patients can appear vomiting, diarrhea and abdominal pain, can disappear after drug withdrawal.

Other reactions have fatigue, chills platelet platelet , fever, headache, dizziness, ataxia, itchy skin, pigmentation, mucositis and pain at the injection site blood vessels, etc. Gastrointestinal reaction, nausea, vomiting, loss of appetite, abdominal distention, diarrhea. Bone marrow suppression, white blood cells and thrombocytopenia, pigmentation, hair loss, dermatitis, ataxia.